Our unique technology platform and expertise accelerate outcomes generation and regulatory reviews for health products. Our HIVE platform is the sole bioinformatics platform used by the FDA for its regulatory evaluation of genomic data and analytical pipelines as part of new precision medicine drug and companion diagnostic approvals, HIVE manages over 15 petabytes of data and contains unique bioinformatics algorithms and pipelines built to power more than 100 regulatory reviews at the FDA in the areas of immuno-oncology, cell therapies, vaccines, anti-virals and other precision medicine therapeutic areas. Combined with HIVE, our Virtual Studies technology is used by more than 2,000 active patients every day to collect, curate and generate regulatory-grade data and powers Real-World Data (RWD) platforms for the Epilepsy Foundation, Multiple Sclerosis Association of America, life sciences companies such as Galderma, and 15 care and research centers such as NYU Langone, George Washington University, UCSF, Yale, Mayo Clinic, Georgetown University and others.